Table 2.
Follow-up variables; immunosuppression, outcome and cause of graft loss
| |
IL-2 plus |
IL-2 minus |
P |
|---|---|---|---|
| (N=149) | (N=83) | ||
| Immunosuppression at 10 weeks |
|
|
|
| CsA |
99 (67%) |
60 (77%) |
ns |
| Tacrolimus |
31 (21%) |
10 (13%) |
ns |
| mTOR inhibitor |
14 (10%) |
9 (12%) |
ns |
| CsA dose (mg/day) |
250.5 ± 73.5 |
255.4 ± 87.8 |
ns |
| CsA C0 concentration |
151.4 ± 56.5 |
183.3 ± 85.6 |
0.01 |
| Tacrolimus dose (mg/day) |
5.65 ± 2.95 |
8.70 ± 4.64 |
ns |
| Tacrolimus concentration |
7.3 ± 2.1 |
9.2 ± 2.3 |
ns |
| Prednisolone dose (mg/day) |
12,4 ± 5.6 |
13.6 ± 5.6 |
ns |
| MMF (mg/day) |
1678.1 ± 402.9 |
1750.0 ± 619.9 |
ns |
| Outcome |
|
|
|
| Delayed graft function |
53 (36%) |
29 (35%) |
ns |
| Acute rejection 90 days post transplant |
29 (20%) |
34 (41%) |
0.001 |
| Acute rejection 180 days post transplant |
38 (26%) |
35 (42%) |
0.01 |
| Steroid-resistant rejection (biopsy proven) |
5 (3%) |
18 (22%) |
< 0.001 |
| C4D positive biopsy |
4 (5%) |
4 (3%) |
ns |
| Cause of graft loss |
|
|
|
| Death with functioning graft |
32 (22%) |
24 (29%) |
ns |
| Primary non-function |
0 |
6 (7%) |
0.002 |
| Primary vascular thrombosis |
3 (2%) |
2 (2%) |
ns |
| Rejection |
5 (3%) |
10 (12%) |
0.02 |
| Recurrent primary disease |
0 |
1 (1%) |
ns |
| Urological complications |
1 (1%) |
0 |
ns |
|
De novo glomerulonephritis |
1 (1%) |
0 |
ns |
| Insufficient graft function |
0 |
2 (2%) |
ns |
| Not specified | 2 (1%) | 2 (2%) | ns |